<DOC>
	<DOCNO>NCT03060642</DOCNO>
	<brief_summary>This study aim elucidate relationship microbiome , inflammation , microenvironment Barrett 's esophagus ( BE ) esophageal adenocarcinoma ( EAC ) , end goal develop non-endoscopic test strategy base pathogenic factor identify patient high risk EAC . To accomplish investigator enroll 100 patient know BE ( 50 dysplasia EAC ) 50 subject without BE undergo upper endoscopy . Prior endoscopy subject undergo three minimally invasive potential screening surveillance test : saliva ( oral microbiome ) , breath test ( exhale volatile organic compound ) , tether capsule sponge sampling ( methylated DNA marker ) . The study evaluate novel test combination clinical anthropometric factor describe optimal strategy BE screen monitoring .</brief_summary>
	<brief_title>The Microenvironment Barrett 's Esophagus</brief_title>
	<detailed_description>The investigator perform multi-center cross-sectional study patient Barrett 's esophagus , without associate dysplasia cancer , control without BE . Enrollment control stratify base use proton pump inhibitor ( PPIs ) . The investigator plan enroll approximate total 150 subject : 100 BE patient ( without associate dysplasia cancer ) - 50 subject non-dysplastic BE - 50 subject BE dysplasia EAC 50 control - 25 control PPIs ( least daily ) - 25 control take PPIs Various test perform sample collect day endoscopy . These test include : saliva sample , electronic nose device testing , tether capsule sponge testing , dietary questionnaire , collection blood gastrointestinal biosamples . Analyses data sample perform address specific aim .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>( BE patient ) History histologically confirm BE , define endoscopicallysuspected BE intestinal metaplasia goblet cell esophageal biopsy BE length M≥2 Taking proton pump inhibitor least daily 3 month prior enrollment Age ≥18 History gastric cancer esophageal squamous cell cancer History gastric esophageal surgery Use antibiotic systemic immunosuppressant within three month prior date endoscopy ( intranasal inhale steroid allow ) Known untreated esophageal stricture uninvestigated dysphagia Inability give inform consent ( BE patient ) History prior endoscopic therapy BE except history prior EMR focal lesion without subsequent ablative therapy permit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Microenvironment</keyword>
	<keyword>Microbiome</keyword>
	<keyword>Screening</keyword>
	<keyword>Barrett Esophagus</keyword>
	<keyword>Esophageal Adenocarcinoma</keyword>
</DOC>